Navigation Links
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Date:9/17/2007

iovascular safety (including atrial fibrillation), found Reclast to be comparable with placebo. Incidence of renal events were similar between the Reclast and placebo group (6.2% versus 5.6%, respectively). Atrial fibrillation serious adverse events occurred in 1.1% of Reclast-treated patients compared to 1.3% of placebo- treated patients. No cases of osteonecrosis of the jaw (ONJ) were seen in the study. The most common adverse events with Reclast were transient post-dose symptoms (such as fever, muscular pain, etc).

About the Study

The Recurrent Fracture Trial was an international, multi-center, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy and safety of Reclast in preventing subsequent fractures in men and women following the surgical repair of a low-trauma hip fracture (i.e., a fall from standing height or less or equivalent force).

It is part of the Novartis HORIZON clinical trial program, one of the most comprehensive drug evaluation programs ever undertaken in the area of metabolic bone diseases involving 13,000 patients in more than 400 centers worldwide.

Men and women between the ages of 50 and 98 who had experienced a recent hip fracture sustained with minimal trauma were randomized to receive a once- yearly infusion of Reclast or placebo within 90 days of undergoing surgery to repair the hip fracture and every 12 months thereafter for up to three years.

The primary endpoint of the study was to determine the effect of Reclast on new clinical fractures following baseline hip fracture. Secondary endpoints included the change in bone mineral density (BMD) in the non- fractured hip measured annually; spine, non-spine and hip fractures; and pre- specified safety endpoints, including death.

About Reclast

Reclast was approved by the US Food and Drug Administration (FDA) on August 17, 2007 as the first and only once-yearly treatment for postmenopausal osteoporosis. Approval
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... 2014 OmPrompt today announces ... help it meet the global demand for customer ... logistics. Albion joins Shackleton Ventures.      ... the past 18 months OmPrompt has underpinned accelerated ... team and its operations. The new funding will ...
(Date:7/25/2014)... N.C. , July 25, 2014  In today,s ... is costly and challenging - as is managing a ... Is it possible - or even preferable ... If so, where can you combine resources and activities, ... These are just a few of ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7OmPrompt Funded for Customer Automation Management Market Expansion 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... April 11, 2011 iCyt Mission Technology, Inc. (iCyt), ... announced the introduction of its new line of 405nm-excited ... Violet™ 421 products are part of the first commercial ... "This exciting new class of fluorescent probes will ...
... 11, 2011 Leading-edge Clinical Pharmacology and Cardiac ... announces the addition of Aziz Karim, BPharm, PhD, ... and advisor to Spaulding,s Clinical Pharmacology/Pharmacokinetic department.   ... the principles of Clinical Pharmacology and rational drug ...
Cached Medicine Technology:iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology 2Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant 2
(Date:7/28/2014)... Amy Norton HealthDay ... Tonsillectomies are commonly done to relieve sleep apnea in children, ... kids, weight gain -- especially if they,re already overweight. ... risk factor for a range of health problems -- including, ... kids who need it. Instead, they said, doctors and ...
(Date:7/28/2014)... Lourdes Health System has partnered with ... wait times for veterans needing medical care. , Lourdes ... state—and the only one in Camden, Burlington and Gloucester ... program (PC3). PC3 gives veterans access to specialty care ... services due to lack of available specialists, long wait ...
(Date:7/28/2014)... 2014 The American Society ... professionals engaged in the field of organ transplantation, ... and Immunology Research Network (TIRN), a professional ... As modern organ transplantation continues to diversify, AST ... provide more opportunities for physicians, scientists and researchers ...
(Date:7/28/2014)... July 28, 2014 With California in ... is welcome news that a fire blanket ... protection is under development by SunSeeker Enterprises, Inc. The ... protect spacecraft from the extreme heat of re-entry into ... firefighters and homes. , “Our firefighters routinely lay their ...
(Date:7/28/2014)... Boston University School of Medicine (BUSM) report variants in ... of developing Alzheimer,s disease (AD). The discovery of this ... options that target PLXNA4 specifically. These findings appear in ... the most frequent age-related dementia affecting 5.4 million Americans ... and more than 40 percent of people age 85 ...
Breaking Medicine News(10 mins):Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Researchers identify potential biomarker for AD 2
... throat strictures, cancer, group warns , FRIDAY, Aug. 31 ... heartburn once a month and more than 15 million ... of Gastroenterology. , Heartburn occurs when stomach contents ... tube that connects the mouth and the stomach. , ...
... to Help Ensure Success, ANAHEIM, Calif., Aug. 31 ... coach Tim Borland,will run a full marathon each day ... to a deadly children,s disease. His "A-T CureTour" -- ... take him,across the country, ending on Nov. 4 with ...
... MTD ) today announced the webcast of its,presentation ... on Friday, September 7, 2007, at 9:10 a.m. Eastern ... the investor relations page on the,Company,s Web site at ... be,available for seven days. METTLER TOLEDO is a ...
... Kan., Aug. 31 Juergen Richt, lead,scientist with ... and an adjunct professor at Iowa State University, ... Distinguished Professor. Richt,s appointment begins in April ... the College of Veterinary,Medicine, is the most prestigious ...
... Inc. (Nasdaq: AMCS ),a leader in radiology and medical image ... investors at the,Thomas Weisel Partners Healthcare Conference 2007 being held in ... -- Thursday, September 6, 2007 ... at 8:35 a.m. (Eastern Time), ...
... shows blocking 2 proteins could mean less invasive treatment ... -- The swelling that normally occurs when a joint ... researchers say. , Publishing in the September issue of ... two immune system proteins -- interleuken-1 and tumor necrosis ...
Cached Medicine News:Health News:Heartburn Can Be a Sign of Serious Disease 2Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 2Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 3Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 4Health News:Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor 2Health News:Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor 3Health News:AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007 2Health News:Swelling After Knee Injury May Hinder Healing 2
... Pectoralis Implants come in three styles. ... is by far the most popular style. ... and are packaged and sold individually, not ... that they are each made for a ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... in the IQmark family elevates your ECG and ... portability, cost-savings and efficient patient care. The IQmark ... the office, clinics and medical centers as well ... used in conjunction with the IQmark Digital ECG ...
24-hour full disclosure , Input range: 5mV , Analog bandwidth: 0.05 to 100Hz (3dB) , Common mode rejection ratio: 60dB , Dimensions: 4.46in. x 2.75in. x 1.02in. (113mm x 70mm x 26mm) , We...
Medicine Products: